A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
12/2002
12/11/2002	EP1264827A1 Process for the preparation of Tosylbenzylformamides
12/11/2002	EP1263959A1 Antibodies to human cd154
12/11/2002	EP1263958A2 Nusap, a gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
12/11/2002	EP1263953A2 Novel family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof
12/11/2002	EP1263786A2 Methods and compositions for immunoregulation
12/11/2002	EP1263767A2 Beta netrin and uses thereof
12/11/2002	EP1263766A1 Adam polynucleotides, polypeptides, and antibodies
12/11/2002	EP1263761A2 Compounds for pdt
12/11/2002	EP1263760A1 Novel compounds
12/11/2002	EP1263756A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263755A2 Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263730A1 Amine derivatives for the treatment of apoptosis
12/11/2002	EP1263728A2 Pde iv inhibiting amides, compositions and pharmaceutical use
12/11/2002	EP1263727A1 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
12/11/2002	EP1263725A1 Novel compounds
12/11/2002	EP1263724A1 Novel compounds
12/11/2002	EP0984943B1 Azacyclooctane and heptane derivatives, their preparation and usein therapy
12/11/2002	EP0981521B1 Novel macrocyclic compounds as metalloprotease inhibitors
12/11/2002	CN1384830A Novel spiroheterocyclic compoundsus reversible inhibitors of cysteine proteases
12/11/2002	CN1384829A Sodium-hydrogen exchanger type 1 inhibitor crystals
12/11/2002	CN1384757A Method for down-regulating GDF-8 activity
12/11/2002	CN1384752A Remedies for nervous diseases
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/11/2002	CN1384104A Usage, kit and composition of pyrrole derivative
12/10/2002	US6492516 Pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
12/10/2002	US6492422 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
12/10/2002	US6492403 Methods of treating C1s-mediated diseases and conditions and compositions thereof
12/10/2002	US6492388 Such as n-(5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide
12/10/2002	US6492387 Isoindolyl and isoquinolinyl aroyl pyrrole compounds
12/10/2002	US6492378 Substituted isoquinoline derivatives and their use as anticonvulsivants
12/10/2002	US6492362 Compounds and compositions as cathepsin S inhibitors
12/10/2002	US6492157 Methods are provided for the treatment of conditions associated with cells proliferation, cells differentiation and cell survival. in particular, the dual-specificity phosphatase dsp-9, and polypeptide variants thereof that
12/05/2002	WO2002097079A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096858A1 Cinnamide derivatives as kcnq potassium channel modulators
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183294 Therapy and prophylaxis of cognitive dysfunction in a human or non-human animal by administering sapogenin derivatives wherein the E and/or F ring of the fused ring system has been cleaved
12/05/2002	US20020183282 For skin, muscle, ocular or gastric mucosal healing
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002	US20020182587 Detection of modulators of cell proliferation; obtain cells, monitor cell proliferation, incubate cell with modulator, detect adjustment in cell proliferation
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182192 Administering bone marrow cells to the mammal, such as allogeneic cells or autologous cells engineered to express dystrophin or other gene products
12/05/2002	DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases
12/05/2002	CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	CA2448894A1 Cinnamide derivatives as kcnq potassium channel modulators
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/04/2002	EP1262191A1 Pharmaceutical compositions comprising recombinant human acid alpha-glucosidase containing mannose 6-phosphate
12/04/2002	EP1261736A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
12/04/2002	EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261328A1 Il-8 receptor antagonists
12/04/2002	EP1261327A2 Adenosine receptor modulators
12/04/2002	EP1100769B1 Aminomethylcarboxylic acid derivatives
12/04/2002	EP1054671B1 New use of ropivacaine for pain management
12/03/2002	US6488164 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
11/2002
11/28/2002	WO2002095034A2 A retinoic acid metabolizing cytochrome p450
11/28/2002	WO2002095025A1 Novel smg-1
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002094833A1 Novel pyrrole derivatives as pharmaceutical agents
11/28/2002	WO2002094821A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	WO2002094795A1 4-aminopyrimidine derivatives
11/28/2002	WO2002094767A2 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002	WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002	WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002	WO2002094220A1 Liquid pharmaceutical composition

1 ... 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 ... 233